Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

222 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.
Tanaka M, Sakai R, Koike R, Komano Y, Nanki T, Sakai F, Sugiyama H, Matsushima H, Kojima T, Ohta S, Ishibe Y, Sawabe T, Ota Y, Ohishi K, Miyazato H, Nonomura Y, Saito K, Tanaka Y, Nagasawa H, Takeuchi T, Nakajima A, Ohtsubo H, Onishi M, Goto Y, Dobashi H, Miyasaka N, Harigai M. Tanaka M, et al. Among authors: dobashi h. Mod Rheumatol. 2012 Nov;22(6):849-58. doi: 10.1007/s10165-012-0615-z. Epub 2012 Feb 22. Mod Rheumatol. 2012. PMID: 22354637
Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules.
Sakai R, Tanaka M, Nanki T, Watanabe K, Yamazaki H, Koike R, Nagasawa H, Amano K, Saito K, Tanaka Y, Ito S, Sumida T, Ihata A, Ishigatsubo Y, Atsumi T, Koike T, Nakajima A, Tamura N, Fujii T, Dobashi H, Tohma S, Sugihara T, Ueki Y, Hashiramoto A, Kawakami A, Hagino N, Miyasaka N, Harigai M; REAL Study Group. Sakai R, et al. Among authors: dobashi h. Ann Rheum Dis. 2012 Nov;71(11):1820-6. doi: 10.1136/annrheumdis-2011-200838. Epub 2012 Apr 13. Ann Rheum Dis. 2012. PMID: 22504558 Free article.
Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study.
Sada KE, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, Ito S, Yamada H, Wada T, Hirahashi J, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan. Sada KE, et al. Among authors: dobashi h. Arthritis Res Ther. 2014 Apr 23;16(2):R101. doi: 10.1186/ar4550. Arthritis Res Ther. 2014. PMID: 24758294 Free PMC article.
The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database.
Sakai R, Cho SK, Nanki T, Koike R, Watanabe K, Yamazaki H, Nagasawa H, Amano K, Tanaka Y, Sumida T, Ihata A, Yasuda S, Nakajima A, Sugihara T, Tamura N, Fujii T, Dobashi H, Miura Y, Miyasaka N, Harigai M; REAL study group. Sakai R, et al. Among authors: dobashi h. Rheumatol Int. 2014 Dec;34(12):1729-36. doi: 10.1007/s00296-014-3045-8. Epub 2014 May 23. Rheumatol Int. 2014. PMID: 24852650
Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study.
Ogata A, Amano K, Dobashi H, Inoo M, Ishii T, Kasama T, Kawai S, Kawakami A, Koike T, Miyahara H, Miyamoto T, Munakata Y, Murasawa A, Nishimoto N, Ogawa N, Ojima T, Sano H, Shi K, Shono E, Suematsu E, Takahashi H, Tanaka Y, Tsukamoto H, Nomura A; MUSASHI Study Investigators. Ogata A, et al. Among authors: dobashi h. J Rheumatol. 2015 May;42(5):799-809. doi: 10.3899/jrheum.140665. Epub 2015 Apr 1. J Rheumatol. 2015. PMID: 25834203 Clinical Trial.
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry.
Sakai R, Cho SK, Nanki T, Watanabe K, Yamazaki H, Tanaka M, Koike R, Tanaka Y, Saito K, Hirata S, Amano K, Nagasawa H, Sumida T, Hayashi T, Sugihara T, Dobashi H, Yasuda S, Sawada T, Ezawa K, Ueda A, Fujii T, Migita K, Miyasaka N, Harigai M; REAL Study Group. Sakai R, et al. Among authors: dobashi h. Arthritis Res Ther. 2015 Mar 23;17(1):74. doi: 10.1186/s13075-015-0583-8. Arthritis Res Ther. 2015. PMID: 25880658 Free PMC article. Clinical Trial.
Comparison of severity classification in Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study.
Sada KE, Harigai M, Amano K, Atsumi T, Fujimoto S, Yuzawa Y, Takasaki Y, Banno S, Sugihara T, Kobayashi M, Usui J, Yamagata K, Homma S, Dobashi H, Tsuboi N, Ishizu A, Sugiyama H, Okada Y, Arimura Y, Matsuo S, Makino H; for Research Committee of Intractable Vasculitis Syndrome and Research Committee of Intractable Renal Disease of the Ministry of Health, Labour, and Welfare of Japan. Sada KE, et al. Among authors: dobashi h. Mod Rheumatol. 2016 Sep;26(5):730-7. doi: 10.3109/14397595.2016.1140274. Epub 2016 Mar 11. Mod Rheumatol. 2016. PMID: 26873424 Free article.
Clinical characteristics of and risk factors for serious infection in Japanese patients within six months of remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis registered in a nationwide, prospective, inception cohort study.
Watanabe-Imai K, Harigai M, Sada KE, Yamamura M, Fujii T, Dobashi H, Amano K, Ito S, Homma S, Kumagai S, Banno S, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labor and Welfare of Japan. Watanabe-Imai K, et al. Among authors: dobashi h. Mod Rheumatol. 2017 Jul;27(4):646-651. doi: 10.1080/14397595.2016.1226468. Epub 2016 Oct 10. Mod Rheumatol. 2017. PMID: 27538706
222 results